Advertisement

International Journal of Hematology

, Volume 75, Issue 1, pp 104–106 | Cite as

Successful Unrelated Bone Marrow Transplantation After Arsenic Trioxide Treatment in a Patient With Relapsed Acute Promyelocytic Leukemia

  • Michiaki Mikoshiba
  • Kazuteru Ohashi
  • Naoko Takei
  • Yoshiki Okuyama
  • Yasuharu Maeda
  • Kiyoshi Hiruma
  • Hideki Akiyama
  • Osamu Fukuhara
  • Akihiro Takeshita
  • Hisashi Sakamaki
Letter to the Editor

Keywords

Acute Promyelocytic Leukemia Arsenic Trioxide Molecular Remission Acute Promyelocytic Leukemia Patient Total Lymphoid Irradiation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hozumi M. Differentiation therapy of leukemia: achievements, limitations and future prospects.Int J Hematol. 1998;68(2):107–129.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Tobita T, Takeshita A, Kitamura K, et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid.Blood. 1997;90:967–973.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Niu C, Yan H, Sun HP, et al. Studies on treatment of acute promye- locytic leukemia with arsenic trioxide: remission induction, follow- up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.Blood. 1999;94:3315–3324.PubMedGoogle Scholar
  4. 4.
    Soignet SL, Maslak P, Wang Z-G, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.N Engl J Med. 1998;339:1341–1348.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Huang SY, Chang CS, Tang JL, et al. Acute and chronic arsenic poi- soning associated with treatment of acute promyelocytic leukemia.Br J Haematol. 1998;103:1092–1095.CrossRefPubMedGoogle Scholar
  6. 6.
    Westervelt P, Brown RA, Douglas RA, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide.Blood. 2001;98:266–271.CrossRefPubMedGoogle Scholar
  7. 7.
    Chen G-Q, Shi X-G, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), I: As2O3 exerts dose-dependent dual effects on APL cells.Blood. 1997;89:3345–3353.PubMedGoogle Scholar
  8. 8.
    Chen G-Q, Ahu J, Shi X-G, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), II: clinical efficacy and pharmacokinetics in relapsed patients.Blood. 1997;89:3354–3360.PubMedGoogle Scholar
  9. 9.
    Soignet SL. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia.Oncologist. 2001;6(suppl 2):11–16.CrossRefPubMedGoogle Scholar
  10. 10.
    Galimberti S, Papineschi F, Carmignani A, et al. Arsenic and all- trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia.Bone Marrow Transplant. 1999;24:345–348.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Asou N, Adachi K, Tamura J, et al. All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy. The Japan Adult Leukemia Study Group (JALSG).Cancer Chemother Pharmacol. 1997;40(suppl):S30-S35.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ohashi K, Tanabe J, Watanabe R, et al. The Japanese multicenter open randomized trial of prophylactic ursodeoxycholic acid for veno-occlusive disease of the liver in patients undergoing stem cell transplantation.Am J Hematol. 2000;64:32–38.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  • Michiaki Mikoshiba
    • 1
  • Kazuteru Ohashi
    • 1
  • Naoko Takei
    • 1
  • Yoshiki Okuyama
    • 1
  • Yasuharu Maeda
    • 1
  • Kiyoshi Hiruma
    • 1
  • Hideki Akiyama
    • 1
  • Osamu Fukuhara
    • 2
  • Akihiro Takeshita
    • 3
  • Hisashi Sakamaki
    • 1
  1. 1.Bone Marrow Transplantation TeamTokyo Metropolitan Komagome HospitalTokyo
  2. 2.Department of Internal MedicineMiyagino HospitalSendai
  3. 3.Third Department of Internal MedicineHamamatsu Medical UniversityHamamatsuJapan

Personalised recommendations